The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Ixekizumab Improves Skin Lesions in Japanese Psoriasis Patients: Eli Lilly Japan
September 30, 2014
- Avigan Administered to Ebola-Infected French Woman: Fujifilm
September 29, 2014
- Sanofi’s 2013 Payments to Healthcare Professionals Down 11%
September 29, 2014
- Novartis Files Panobinostat for Multiple Myeloma in Japan
September 29, 2014
- Sanofi Opens Asia Pacific Development Hub in Shanghai
September 29, 2014
- Ribomic Goes Public, Aims to Swing to Black on Aptamers
September 26, 2014
- NBI Paid 14.6 Billion Yen to Healthcare Professionals in 2013
September 26, 2014
- Takeda to Invest 2.5 Billion Yen in US Firm for New Drug Development
September 26, 2014
- OncoTherapy Science Appoints Masaharu Mori, Formerly of Shionogi and Novartis Pharma, as New President
September 26, 2014
- Eisai Sets Up Director Position for Pariet
September 26, 2014
- US FDA Accepts NDA for Abilify Successor Brexpiprazole: Otsuka, Lundbeck
September 26, 2014
- AZ Managed to Speed Up Pilot R&D Projects under New Structure: President
September 25, 2014
- MSD Paid 19.4 Billion Yen to Healthcare Professionals in 2013
September 25, 2014
- Gilead Sciences Submits NDA for Ledipasvir/Sofosbuvir Combination for Genotype 1 Chronic Hepatitis C
September 25, 2014
- AnGes MG to Start Collategene Administration in PIII Study in US as Early as October
September 25, 2014
- Ibandronate Oral Agent to Be Filed for Japan Approval in 2015: Chugai, Taisho
September 24, 2014
- Meiji Seika Pharma Seeks New Indication for Laserphyrin
September 24, 2014
- Mediceo Sets to Increase Qualified Reps to 2,000, Enter Contract PMS Biz within 3 Years
September 22, 2014
- Bristol-Myers Submits NDA for Malignant Melanoma Drug Ipilimumab
September 22, 2014
- Additional Indication Approved for MTPC’s Telavic
September 22, 2014
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…